Bicara Therapeutics Financials - Benzinga

Bicara Therapeutics Inc

BCAXNASDAQ

Trade with Public

Trade with Public

$23.51

-0.12-0.51%

Last update: Aug 14, 9:30 AM

Earnings: Q2 2026 Earnings were released on Tue Aug 11th, before the market open

Conference Call: The most recent conference call started at 8:30 AM, 3 days ago

Click to view the webcast

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Bicara Therapeutics Financials

Bicara Therapeutics (BCAX) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

Bicara Therapeutics Analysts Raise Their Forecasts After Q2 Results

Bicara Therapeutics (BCAX) reported a narrower-than-expected loss in Q2. Analysts raised price targets, but shares dipped 14.3% to $23.76. #BCAX #earnings

Avi Kapoor

PRO
Bicara Therapeutics Q2 EPS $(0.82) Beats $(0.84) Estimate

Bicara Therapeutics (NASDAQ:BCAX) reported quarterly losses of $(0.82) per share which beat the analyst consensus estimate of $(0.84) by 2.38 percent. This is a 64 percent decrease over losses of $(0.50) per share from

Benzinga Newsdesk

PRO
Bicara Therapeutics Q1 EPS $(0.93) Misses $(0.68) Estimate

Bicara Therapeutics (NASDAQ:BCAX) reported quarterly losses of $(0.93) per share which missed the analyst consensus estimate of $(0.68) by 36.76 percent. This is a 36.76 percent decrease over losses of $(0.68) per share

Benzinga Newsdesk

Earnings Scheduled For May 11, 2026

Benzinga Insights

PRO
Bicara Therapeutics Q4 EPS $(0.68), Inline

Bicara Therapeutics (NASDAQ:BCAX) reported quarterly losses of $(0.68) per share which met the analyst consensus estimate. This is a 74.36 percent decrease over losses of $(0.39) per share from the same period last year.

Benzinga Newsdesk

Earnings Scheduled For March 30, 2026

Benzinga Insights